The risk score was positively correlated with the expression of the checkpoint markers, PD-1 (Figure 6C), PD-L1 (Figure 6D) and CTLA-4 (Figure 6E), implicating the potential roles of the signature model in the response to immunotherapy in BLCA patients. The gene discussed is CTLA4; the disease is bladder transitional cell carcinoma.